Key result
The SCORE2 risk model initially underestimated cardiovascular risk in cancer patients but achieved a C-statistic of 0.693 (95% CI 0.643-0.743) for predicting fatal and non-fatal CVD risk.
Why the study?
Cardio-oncology guidelines recommend SCORE2 and SCORE2-OP for cardiovascular risk stratification in cancer patients, but these models have not been validated or specifically adapted for cancer populations.
Do the SCORE2 and SCORE2-OP models accurately predict 10-year fatal and non-fatal CVD risk in cancer patients?
Cohort (n=1,622)
Do the SCORE2 and SCORE2-OP models accurately predict 10-year fatal and non-fatal CVD risk in cancer patients?
Effect estimate: C-statistic 0.693 (95% CI 0.643-0.743)
SCORE2 underestimates CVD risk in cancer patients but can be a valuable risk stratification tool after recalibration.
No takes yet. Share an insight, caveat, or question.
May warrant cautious use of SCORE2 in cancer patients; leaves open need for recalibrated cardio-oncology models.
Gynnild et al. (2025) conducted a cohort in cancer (n=1,622). SCORE2 and SCORE2-OP risk models was evaluated on composite of myocardial infarction (MI), stroke, or CVD mortality (C-statistic 0.693, 95% CI 0.643-0.743). The SCORE2 risk model initially underestimated cardiovascular risk in cancer patients but achieved a C-statistic of 0.693 (95% CI 0.643-0.743) for predicting fatal and non-fatal CVD risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: